- Home
- MTLS vs SCPH Comparison
MTLS vs SCPH Comparison
Compare MTLS & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- SCPH
- Stock Information
- Founded
- MTLS 1990
- SCPH 2013
- Country
- MTLS Belgium
- SCPH United States
- Employees
- MTLS N/A
- SCPH N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- MTLS Technology
- SCPH Health Care
- Exchange
- MTLS Nasdaq
- SCPH Nasdaq
- Market Cap
- MTLS 349.7M
- SCPH 299.0M
- IPO Year
- MTLS 2014
- SCPH 2017
- Fundamental
- Price
- MTLS $5.17
- SCPH $5.63
- Analyst Decision
- MTLS
- SCPH Buy
- Analyst Count
- MTLS 0
- SCPH 3
- Target Price
- MTLS N/A
- SCPH $12.00
- AVG Volume (30 Days)
- MTLS 121.7K
- SCPH 2.4M
- Earning Date
- MTLS 10-23-2025
- SCPH 11-12-2025
- Dividend Yield
- MTLS N/A
- SCPH N/A
- EPS Growth
- MTLS N/A
- SCPH N/A
- EPS
- MTLS 0.11
- SCPH N/A
- Revenue
- MTLS $311,850,851.00
- SCPH $49,969,000.00
- Revenue This Year
- MTLS $2.98
- SCPH $104.30
- Revenue Next Year
- MTLS $7.09
- SCPH $76.06
- P/E Ratio
- MTLS $47.83
- SCPH N/A
- Revenue Growth
- MTLS 2.98
- SCPH 107.79
- 52 Week Low
- MTLS $3.93
- SCPH $1.94
- 52 Week High
- MTLS $9.69
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- MTLS 51.80
- SCPH 63.97
- Support Level
- MTLS $4.96
- SCPH $4.33
- Resistance Level
- MTLS $5.24
- SCPH $5.62
- Average True Range (ATR)
- MTLS 0.18
- SCPH 0.04
- MACD
- MTLS 0.02
- SCPH -0.01
- Stochastic Oscillator
- MTLS 64.29
- SCPH 86.67
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.